Visakorpi T - Search Results

1

Long noncoding RNA in prostate, bladder, and kidney cancer.

Martens-Uzunova ES, Böttcher R, Croce CM, Jenster G, Visakorpi T, Calin GA. Martens-Uzunova ES, et al. Among authors: visakorpi t. Eur Urol. 2014 Jun;65(6):1140-51. doi: 10.1016/j.eururo.2013.12.003. Epub 2013 Dec 14. Eur Urol. 2014. PMID: 24373479 Review.

2

New prognostic factors in prostatic carcinoma.

Visakorpi T, Kallioniemi OP, Koivula T, Isola J. Visakorpi T, et al. Eur Urol. 1993;24(4):438-49. doi: 10.1159/000474347. Eur Urol. 1993. PMID: 8287885 Review. No abstract available.

3

Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade.

Palmberg C, Koivisto P, Hyytinen E, Isola J, Visakorpi T, Kallioniemi OP, Tammela T. Palmberg C, et al. Among authors: visakorpi t. Eur Urol. 1997;31(2):216-9. doi: 10.1159/000474453. Eur Urol. 1997. PMID: 9076469

4

Androgen receptor gene and hormonal therapy failure of prostate cancer.

Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP. Koivisto P, et al. Among authors: visakorpi t. Am J Pathol. 1998 Jan;152(1):1-9. Am J Pathol. 1998. PMID: 9422516 Free PMC article. Review.

5

Molecular biology of progression of prostate cancer.

Nupponen N, Visakorpi T. Nupponen N, et al. Among authors: visakorpi t. Eur Urol. 1999;35(5-6):351-4. doi: 10.1159/000019907. Eur Urol. 1999. PMID: 10325488 Review.

6

PSA decline is an independent prognostic marker in hormonally treated prostate cancer.

Palmberg C, Koivisto P, Visakorpi T, Tammela TL. Palmberg C, et al. Among authors: visakorpi t. Eur Urol. 1999 Sep;36(3):191-6. doi: 10.1159/000067996. Eur Urol. 1999. PMID: 10450001

7

Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.

Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T. Palmberg C, et al. Among authors: visakorpi t. J Urol. 2000 Dec;164(6):1992-5. J Urol. 2000. PMID: 11061898

8

Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer.

Isola J, Auvinen A, Poutiainen M, Kakkola L, Järvinen TA, Määttänen L, Stenman UH, Tammela T, Hakama M, Visakorpi T. Isola J, et al. Among authors: visakorpi t. J Urol. 2001 May;165(5):1569-74. J Urol. 2001. PMID: 11342919 Clinical Trial.

9

Expression of ERalpha and ERbeta in prostate cancer.

Linja MJ, Savinainen KJ, Tammela TL, Isola JJ, Visakorpi T. Linja MJ, et al. Among authors: visakorpi t. Prostate. 2003 May 15;55(3):180-6. doi: 10.1002/pros.10242. Prostate. 2003. PMID: 12692783

10

The molecular genetics of prostate cancer.

Visakorpi T. Visakorpi T. Urology. 2003 Nov;62(5 Suppl 1):3-10. doi: 10.1016/s0090-4295(03)00776-3. Urology. 2003. PMID: 14607212 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

293 results

Search Page